Testing pembrolizumab after CYAD-101 plus FOLFOX in colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This early-phase study tests whether adding pembrolizumab after CYAD-101 and FOLFOX chemotherapy can help treat metastatic colon or rectal cancer. It is mainly looking for safety and signs of how well the treatment works in people whose cancer has not responded to prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colon or rectal cancer has spread (metastatic) and cannot be removed by surgery
- Your tumor is not MSI-H; it is mismatch-repair proficient (pMMR)
- Your cancer has a measurable spot the doctors can track on scans
- Your cancer has come back or grown after at least one treatment that included FOLFOX, and you are scheduled to get FOLFOX
- You had no more than mild nerve side effects (up to grade 1) from your last chemo
- You can do daily activities fairly well (ECOG 0 or 1), and you can have a new tumor biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests CYAD-101, an immune-cell treatment made from donor T-cells, given with standard chemotherapy. It is for people with colon or rectal cancer that has spread and has not responded to prior treatments.
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
This Phase 2 study tests adding anlotinib and penpulimab to irinotecan for colorectal cancer that has come back or spread after earlier chemotherapy. It may help shrink tumors and control the disease when standard first-line treatment no longer works.
This phase 2 trial tests whether injecting a vaccine into the tumor, along with pembrolizumab (an immune medicine), can improve outcomes for people with early-stage, localized colon cancer that does not have certain DNA mismatch repair changes (pMMR). It’s done around the time you plan to have curative surgery, with the goal of boosting the immune system against the cancer.
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
This trial tests if the immunotherapy drug pembrolizumab can shrink colon cancers with specific genetic features (dMMR/MSI-H) before surgery. If the tumor responds well, some patients might avoid chemotherapy after surgery. It is for people with newly diagnosed, localized colon or upper rectal cancer.
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.